{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:28:51Z","timestamp":1791232131103,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gene coding mutations found in sodium glucose co-transporters (SGLTs) are known to cause renal glucosuria. SGLT2 inhibitors have recently been shown to be effective hypoglycemic agents as well as possessing cardiovascular and renal protective properties. These beneficial effects have to some extent, been attributed to weight loss and reduced blood pressure. The aim of the current study was to evaluate the prevalence of renal glucosuria amongst a large cohort of Israeli adolescents and to investigate whether renal glucosuria is associated with lower body weight and lower blood pressure values.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Medical and socio-demographic data were collected from the Israeli Defense Force\u2019s conscription center\u2019s database. A cross-sectional study to evaluate the association between conscripts diagnosed as overweight [BMI percentiles of \u2265\u200985 and &lt;\u200995 and obesity (\u2265\u200995 BMI percentile)] and afflicted with renal glucosuria was conducted. In addition, we assessed the association of renal glucosuria with elevated diastolic and systolic blood pressure. Multinomial regression models were used.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The final study cohort comprised 2,506,830 conscripts of whom 1108 (0.044%) were diagnosed with renal glucosuria, unrelated to diabetes mellitus, with males twice as affected compared to females. The adjusted odds ratio for overweight and obesity was 0.66 (95% CI 0.50\u20130.87) and 0.62 (95% CI 0.43\u20130.88), respectively. Adolescents afflicted with renal glucosuria were also less likely to have an elevated systolic blood pressure of 130\u2013139\u00a0mmHg with an adjusted odds ratio of 0.74 (95% CI 0.60\u20130.90).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Renal glucosuria is associated with lower body weight and obesity as well as with lower rates of elevated systolic blood pressure.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-019-0929-7","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T09:03:01Z","timestamp":1569402181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: results of a nationwide cross-sectional study of 2.5 million adolescents"],"prefix":"10.1186","volume":"18","author":[{"given":"Boris","family":"Fishman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gadi","family":"Shlomai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilad","family":"Twig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estela","family":"Derazne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Tenenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique Z.","family":"Fisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Leiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8353-0661","authenticated-orcid":false,"given":"Ehud","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"issue":"1","key":"929_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","volume":"14","author":"RA DeFronzo","year":"2012","unstructured":"DeFronzo RA, Davidson JA, del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5\u201314. \n                    https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01511.x\n                    \n                  .","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"929_CR2","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1053\/j.ajkd.2008.12.031","volume":"53","author":"O Marsenic","year":"2009","unstructured":"Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53(5):875\u201383. \n                    https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.031\n                    \n                  .","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"929_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2796.2006.01746.x","volume":"261","author":"EM Wright","year":"2007","unstructured":"Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261(1):32\u201343. \n                    https:\/\/doi.org\/10.1111\/j.1365-2796.2006.01746.x\n                    \n                  .","journal-title":"J Intern Med"},{"issue":"1","key":"929_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-017-0371-7","volume":"24","author":"L Szablewski","year":"2017","unstructured":"Szablewski L. Distribution of glucose transporters in renal diseases. J Biomed Sci. 2017;24(1):1\u201312. \n                    https:\/\/doi.org\/10.1186\/s12929-017-0371-7\n                    \n                  .","journal-title":"J Biomed Sci"},{"issue":"6","key":"929_CR5","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/S1262-3636(14)72691-6","volume":"40","author":"MC Thomas","year":"2014","unstructured":"Thomas MC, Jandeleit-Dahm K, Bonnet F. Beyond glycosuria: exploring the intrarenal effects of SGLT-2 inhibition in diabetes. Diabetes Metab. 2014;40(6):S17\u201322. \n                    https:\/\/doi.org\/10.1016\/S1262-3636(14)72691-6\n                    \n                  .","journal-title":"Diabetes Metab"},{"issue":"3","key":"929_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1023\/A:1005632012591","volume":"23","author":"GK Brown","year":"2000","unstructured":"Brown GK. Glucose transporters: structure, function and consequences of deficiency. J Inherit Metab Dis. 2000;23(3):237\u201346. \n                    https:\/\/doi.org\/10.1023\/A:1005632012591\n                    \n                  .","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"929_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2215\/CJN.04010609","volume":"5","author":"R Santer","year":"2010","unstructured":"Santer R, Calado J. Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5(1):133\u201341. \n                    https:\/\/doi.org\/10.2215\/CJN.04010609\n                    \n                  .","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"929_CR8","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00467-012-2109-9","volume":"27","author":"H Lee","year":"2012","unstructured":"Lee H, Han KH, Park HW, et al. Familial renal glucosuria: a clinicogenetic study of 23 additional cases. Pediatr Nephrol. 2012;27(7):1091\u20135. \n                    https:\/\/doi.org\/10.1007\/s00467-012-2109-9\n                    \n                  .","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"929_CR9","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.lfs.2004.10.016","volume":"76","author":"S Tazawa","year":"2005","unstructured":"Tazawa S, Yamato T, Fujikura H, et al. SLC5A9\/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-d-glucitol, and fructose. Life Sci. 2005;76(9):1039\u201350. \n                    https:\/\/doi.org\/10.1016\/j.lfs.2004.10.016\n                    \n                  .","journal-title":"Life Sci"},{"issue":"1","key":"929_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"RA DeFronzo","year":"2017","unstructured":"DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11\u201326. \n                    https:\/\/doi.org\/10.1038\/nrneph.2016.170\n                    \n                  .","journal-title":"Nat Rev Nephrol"},{"issue":"22","key":"929_CR11","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1504720\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"929_CR12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1812389","author":"SD Wiviott","year":"2018","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018. \n                    https:\/\/doi.org\/10.1056\/nejmoa1812389\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"7","key":"929_CR13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canvas. N Engl J Med. 2017;377(7):644\u201357. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1611925\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"1","key":"929_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-017-0547-1","volume":"16","author":"H Zou","year":"2017","unstructured":"Zou H, Zhou B, Xu G. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetol. 2017;16(1):1\u201311. \n                    https:\/\/doi.org\/10.1186\/s12933-017-0547-1\n                    \n                  .","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"929_CR15","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2337\/dc16-0041","volume":"39","author":"M Abdul-Ghani","year":"2016","unstructured":"Abdul-Ghani M, Del Prato S, Chilton R, De Fronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG Outcome study. Diabetes Care. 2016;39(5):717\u201325. \n                    https:\/\/doi.org\/10.2337\/dc16-0041\n                    \n                  .","journal-title":"Diabetes Care"},{"key":"929_CR16","unstructured":"Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data. 2000;(314):1\u201327. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11183293\n                    \n                  ."},{"issue":"1","key":"929_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0903-4","volume":"18","author":"AY Kluger","year":"2019","unstructured":"Kluger AY, Tecson KM, Lee AY, et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019;18(1):1\u201313. \n                    https:\/\/doi.org\/10.1186\/s12933-019-0903-4\n                    \n                  .","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"929_CR18","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3346\/jkms.2017.32.6.985","volume":"32","author":"MS Kim","year":"2017","unstructured":"Kim MS, Lee DY. Urinary glucose screening for early detection of asymptomatic type 2 diabetes in Jeonbuk province Korean schoolchildren. J Korean Med Sci. 2017;32(6):985\u201391. \n                    https:\/\/doi.org\/10.3346\/jkms.2017.32.6.985\n                    \n                  .","journal-title":"J Korean Med Sci"},{"issue":"1","key":"929_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/ped.13456","volume":"60","author":"T Urakami","year":"2018","unstructured":"Urakami T, Yoda M, Yoshida K, Mine Y, Aoki M, Suzuki J. Renal glucosuria in schoolchildren: clinical characteristics. Pediatr Int. 2018;60(1):35\u201340. \n                    https:\/\/doi.org\/10.1111\/ped.13456\n                    \n                  .","journal-title":"Pediatr Int"},{"issue":"10166","key":"929_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X\n                    \n                  .","journal-title":"Lancet"},{"issue":"9896","key":"929_CR21","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/s0140-6736(13)60683-2","volume":"382","author":"WT Cefalu","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon K-HH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52\u00a0week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941\u201350. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(13)60683-2\n                    \n                  .","journal-title":"Lancet"},{"issue":"6","key":"929_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","volume":"156","author":"JPH Wilding","year":"2012","unstructured":"Wilding JPH, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405\u201315. \n                    https:\/\/doi.org\/10.7326\/0003-4819-156-6-201203200-00003\n                    \n                  .","journal-title":"Ann Intern Med"},{"issue":"3","key":"929_CR23","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, Ljunggren \u00d6, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020\u201331. \n                    https:\/\/doi.org\/10.1210\/jc.2011-2260\n                    \n                  .","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"929_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0852-y","volume":"18","author":"A Schork","year":"2019","unstructured":"Schork A, Saynisch J, Vosseler A, et al. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc Diabetol. 2019;18(1):1\u201312. \n                    https:\/\/doi.org\/10.1186\/s12933-019-0852-y\n                    \n                  .","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"929_CR25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/00325481.2016.1169894","volume":"128","author":"L Blonde","year":"2016","unstructured":"Blonde L, Stenl\u00f6f K, Fung A, Xie J, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016;128(4):371\u201380. \n                    https:\/\/doi.org\/10.1080\/00325481.2016.1169894\n                    \n                  .","journal-title":"Postgrad Med"},{"issue":"7","key":"929_CR26","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2337\/dc13-3055","volume":"37","author":"J Rosenstock","year":"2014","unstructured":"Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815\u201323. \n                    https:\/\/doi.org\/10.2337\/dc13-3055\n                    \n                  .","journal-title":"Diabetes Care"},{"key":"929_CR27","doi-asserted-by":"publisher","first-page":"650","DOI":"10.2337\/dc08-1863","volume":"32","author":"JF List","year":"2009","unstructured":"List JF, Tang W, Woo V, Fiedorek FT, Morales E. Sodium-glucose cotransport inhibition. Emerg Treat Technol. 2009;32:650\u20137. \n                    https:\/\/doi.org\/10.2337\/dc08-1863\n                    \n                  .","journal-title":"Emerg Treat Technol"},{"issue":"2","key":"929_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/dom.12188","volume":"16","author":"CS Kovacs","year":"2014","unstructured":"Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16(2):147\u201358. \n                    https:\/\/doi.org\/10.1111\/dom.12188\n                    \n                  .","journal-title":"Diabetes Obes Metab"},{"key":"929_CR29","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.2337\/dc11-0606","volume":"34","author":"MA Nauck","year":"2011","unstructured":"Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin. Diabetes Care. 2011;34:2015\u201322. \n                    https:\/\/doi.org\/10.2337\/dc11-0606\n                    \n                  .","journal-title":"Diabetes Care"},{"issue":"10","key":"929_CR30","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2337\/dc10-0612","volume":"33","author":"E Ferrannini","year":"2010","unstructured":"Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise. Diabetes Care. 2010;33(10):2217\u201324. \n                    https:\/\/doi.org\/10.2337\/dc10-0612\n                    \n                  .","journal-title":"Diabetes Care"},{"issue":"4","key":"929_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","volume":"8","author":"WL Baker","year":"2014","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262\u201375. \n                    https:\/\/doi.org\/10.1016\/j.jash.2014.01.007\n                    \n                  .","journal-title":"J Am Soc Hypertens"},{"issue":"1","key":"929_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12933-017-0511-0","volume":"16","author":"M Pfeifer","year":"2017","unstructured":"Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017;16(1):29. \n                    https:\/\/doi.org\/10.1186\/s12933-017-0511-0\n                    \n                  .","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"929_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-016-0485-3","volume":"16","author":"A Grossman","year":"2017","unstructured":"Grossman A, Grossman E. Blood pressure control in type 2 diabetic patients. Cardiovasc Diabetol. 2017;16(1):1\u201315. \n                    https:\/\/doi.org\/10.1186\/s12933-016-0485-3\n                    \n                  .","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"929_CR34","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s10157-017-1528-0","volume":"22","author":"K Iseki","year":"2018","unstructured":"Iseki K, Konta T, Asahi K, et al. Glucosuria and all-cause mortality among general screening participants. Clin Exp Nephrol. 2018;22(4):850\u20139. \n                    https:\/\/doi.org\/10.1007\/s10157-017-1528-0\n                    \n                  .","journal-title":"Clin Exp Nephrol"},{"issue":"2 Pt 1","key":"929_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0895-7061(98)00186-1","volume":"12","author":"E Kouidi","year":"1999","unstructured":"Kouidi E, Fahadidou-Tsiligiroglou A, Tassoulas E, Deligiannis A, Coats A. White coat hypertension detected during screening of male adolescent athletes. Am J Hypertens. 1999;12(2 Pt 1):223\u20136.","journal-title":"Am J Hypertens"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0929-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-019-0929-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0929-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T01:29:16Z","timestamp":1600910956000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0929-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,25]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["929"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0929-7","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,25]]},"assertion":[{"value":"8 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the IDF\u2019s ethics committee, who waived the requirement for informed consent since data were obtained from medical records without the participation of patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}